EasyDigital JAK2

QuanStudio™ Absolute Q™ Digital PCR System

08337245 for EasyDigital JAK2 (48 reactions)

The recurrent somatic mutation **JAK2 V617F**, identified in 2005, is a key event in the development of BCR-ABL–negative myeloproliferative neoplasms **(MPN)**. It is detected in >95% of polycythemia vera **(PV)**, 50–60% of essential thrombocythemia **(ET)** and ~50% of primary myelofibrosis **(PMF)**, and is absent (0%) in chronic myeloid leukemia **(CML)**.

The mutation is a single-nucleotide change at position 1849 (exon 14) that substitutes a valine for a phenylalanine at position 617 of the protein (JH2 domain), driving constitutive activation of the JAK2 kinase. Since the 2008 WHO criteria, its detection is a major criterion for the diagnosis of BCR-ABL–negative MPN.

- **dPCR system: QuantStudio™ Absolute Q™ Digital PCR System**
- **Number of reactions: 48**
- **4–16 samples per dPCR run (MAP16 Plate)**
- **The assay includes probes for the JAK2 V617F mutant and wild-type alleles**
- **Software easy to use**
- **Results in copies/µl and mutant allele fraction (%)**

The **EasyDigital JAK2** determines the presence of the **V617F** mutation with high sensitivity and specificity using allele-specific TaqMan™ probes, and has been designed for diagnosis and quantification of mutant allele burden.

The EasyDigital JAK2 has been validated for the QuantStudio™ Absolute Q™ Digital PCR System. Digital PCR (dPCR) is a precise technique that allows absolute nucleic acid quantification of low amounts of targets.

Assay in the process of CE-IVD marking for use in In-Vitro diagnostics





Producto distribuido por Proquinorte S.A. Edif. 208, 48170 Zamudio, Vizcaya
Absolute QTM is trademark of © 2021 Thermo Fisher Scientific Inc. (Carlsbad, EEUU).

hoopbio.com